July 15, 2021 7:45am
Pre-open indications: 2 BUYs: BLUE, SAGE; 3 SELLs: CLLS, EDIT, NTLA; 1 Maintain SELL: BSTG
My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session
Remember that overnight action in Dow futures and elsewhere doesn't necessarily translate into actual trading in the next regular stock market session.
I challenge the status quo to achieve what most believe is impossible, each session breaking down tactical ways to earn.
Dow futures are DOWN -0.60% (-208 points), S&P futures are DOWN -0.49% (-22 point) and NASDAQ futures are DOWN -0.14% (-21 points)
Futures continue to fluctuate i.e., sliding in the pre-open on Thursday
European stocks were lower as the pan-European Stoxx 600 dropped 0.3% by mid-morning,
Asia-Pacific stocks were mixed as China reported its Q2 gross domestic product (GDP) rose.
Data Docket: Day two of Congressional testimony from Fed Chief Powell and weekly jobless claims data
- Powell said the economy is “a ways off” from where it needs to be for the central bank to change policy;
- Economists are expecting first-time jobless claims of 360,000, compared to 373,000 for the week ended July 3.
Henry’omics:
Futures fell as investors focused on the continuing rollover in bond yields, which raised questions about whether the global economic recovery will live up to expectations, especially with variants of Covid-19 spreading. <CNBC>
Wednesday’s evening’s recap: “back to staring into the abyss. Fundamentals are broken and expectation is in the toilet while Biostage (BSTG) pumps its way to exercise outstanding warrants – their only access to raise capital” …
- The Nasdaq closed DOWN – 32.70 points (-0.22%)
- The IBB closed down -1.27% and XBI closed down -2.78%
- Sector volume was NADA with 0 of the 3-upside having higher than the 3-month average volume with very LOW volume of 2 of 31-downside having higher than the 3-month average volume;
- The CBOE Volatility Index (VVIX: INDEX) was down -0.79 points or -4.61% at 16.33
- Wednesday’s percentage (%) of the 3-upside were +0.27% (PSTI) to +3.64% (BSTG) while the 31-downside ranges from -0.64% (SLDB) to -7.08% (PGEN);
Q3/21: 3 positive and 6 negative close
Q2/21:
- June: 15 positive and 8 negative closes
- May: 8 positive, 12 negative closes and 1 holiday
- April: 11 negative and 10 positive closes
Q1/21:
- March: 10 positive, 12 negative and 1 neutral closes
- February: 9 positive, 10 negative closes and 1 holiday
- January: 10 positive, 9 negative closes and 1 holiday
Companies in my headlights – It’s your decision; I provide an idea and context:
The Biostage (BSTG) Chronicles - Maintaining Sell – Could the share price stay up if it wasn’t being “pumped”?
Biostage (BSTG) closed up +$0.06 to $1.71 with 996 shares traded after Tuesday’s +$0.14 to $1.64 with 1,100 shares traded after Monday’s flat with 2,600 shares traded Friday’s ($1.50) flat with 1,100 shares traded post last Thursday’s flat with 200 shares traded,
Question#1: WHY no clinical trial initiation after an IND approval that is a year and ½ old?
MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.
The morning’s indications:
Bounce-back BUYs:
bluebird bio (BLUE) closed down -$1.10 to $27.76 after Tuesday’s $28.86 and Monday’s $29.79 and last Friday’s $30.57 with a positive +$0.12 or +0.43% pre-market indication.
Sage Therapeutics (SAGE) closed down -$3.39 to $49.07 with a positive +$0.93 or +1.07% pre-market indication.
SELL:
Cellectis SA (CLLS) closed down -$0.80 to $13.94 and has a negative -0.22 or -1.58% pre-market indication.
Editas Medicine (EDIT) closed down -$0.72 to $43.08 after Tuesday’s $43.80, Monday’s $46.07 and Friday’s $48.57 although with a negative -$0.31 or -0.72% pre-market indication.
Intellia Therapeutics (NTLA) closed down -$2.26 to $141.06 and has a negative -$1.16 or -0,82% pre-market indication.
The BOTTOM LINE: Is this yet, another session of “any which way” works … I also continue to MAINTAIN, this is a confused sector as sentiment rages and fades, momentum is usurped, fundamentals are being ignored.
It takes courage to not being discouraged by “our” universe of cell and gene therapy equities or sector …
My focus has always been “indication and warning analysis” … my advice, trim and skim any new highs if one can!” I also see a number of lows that could be in the “pick-up” stock game.
Q2 earnings LPS (loss-per-share) release date are being divulged
My motto, never leave an investor uninformed about what I know!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
